Saudi Aramco Commences Secondary Public Offering - Adviser
Tesla Inc: Model 3 Performance Version Will Begin Sales in China, First Deliveries Expected to Begin Mid-June
Yemen's Houthis Say They Targeted 'maina Ship, Aloraiq Ship and Abliani Ship'
U.S. State Department Says United States, Egypt, and Qatar Jointly Call on Both Hamas and Israel to Finalize Agreement Embodying Principles Outlined by Biden
Israel's Smotrich: Balks at Any Israeli Troop Withdrawal, Return of Palestinians to North Gaza, Mass Prisoner-Release
Israel's Smotrich: Demands Pressing Gaza Offensive Until Hamas Destroyed and All Hostages Returned
Israel's Ben-Gvir: IF Netanyahu Enters Deal That Ends Gaza War With Hamas Untoppled, We Will Bring Down Government
Israel's Ben-Gvir: Won't Agree to Ending Gaza War Without Total Elimination of Hamas
Ukmto Says Vessel and Crew Reported Safe, Vessel Is Proceeding to Its Next Port of Call
Ukmto Says, Regarding Incident West of Yemen's Hodeidah, Captain Witnessed Explosion a Significant Distance From Vessel
U.S. Secretary of State Blinken Spoke by Phone With Top Officials From United Arab Emirates, Qatar and Egypt Regarding Gaza Peace Plan - Spokesperson
Teva Presents First Real-World Data From the Impact-TD Registry Study at Psych Congress Elevate 2024
Kuwait's Emir Appoints Sabah Khalid Al-Hamad Al-Sabah as Crown Prince -State News Agency
Ambrey Says It Has Received Information Indicating Missile Activity 47Nm West of Yemen's Hodeidah
Launch of Boeing's First Starliner Mission With Astronauts Aboard Called off for at Least 24 Hours Over Technical Issue - Boeing Official
Black Diamond Therapeutics: Results From Phase 1 Dose Escalation Trial of Bdtx-1535 in GBM Patients Demonstrated Favorable Safety and Tolerability
Werewolf Therapeutics: Wtx-124 Shown to Be Clinically Active and Generally Well-Tolerated in Patients
Werewolf Therapeutics to Present Data From Ongoing Phase 1/1B Clinical Trial of Wtx-124 as Monotherapy and in Combination With Pembrolizumab in Solid Tumors
Y-mAbs Announces Publication of Preclinical GD2-Sada Data at 2024 Asco Annual Meeting
Suntory Says the Company Is Not in Negotiations With Boston Beer About Acquisition
Nuvation Bio Inc : Aim to Become a Commercial-Stage Organization by End of 2025
Nuvation Bio: Look Forward to Further Advancing Taletrectinib and Plan to Share Results From Global, Pivotal Trust-II Study by End of 2024
Nuvation Bio Inc : Responses Were Durable With Long-Term Follow-up; 71% of Tki-Naïve Patients Were Still Progression-Free at Two Years
Nuvation Bio Inc : Tumors Shrank in 91% of Taletrectinib-Treated Patients With Advanced Ros1-Positive Nsclc Who Were Ros1 Tki-Naïve
Nuvation Bio Announces Data From Pivotal Phase 2 Trust-I Study of Its Investigational Ros1 Inhibitor, Taletrectinib, Are Published in the Journal of Clinical Oncology and Reported at 2024 Asco Annual Meeting
Jazz Pharmaceuticals: Results Highlight Clinically Meaningful Benefits of Sustained and Durable Responses With Continued Treatment With Zanidatamab
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 Asco Annual Meeting
Krazati (Adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients With Pretreated Locally Advanced or Metastatic Krasg12C-Mutated Non-Small Cell Lung Cancer
Tiumbio Co Ltd : Data From Full Phase 1B Trial, Which Includes 18 Patients, Will Be Available in Second Half of 2024
Tiumbio Co: Tu2218 Was Well-Tolerated as a Monotherapy and Combination Therapy With Pembrolizumab, With No Dose Limiting Toxicities (Dlts) to Date